CCCC - C4 Therapeutics Inc Stock Price, Fair Value and News

6.49USD+0.05 (+0.78%)Market Closed

Market Summary

USD6.49+0.05

Market Closed

0.78%

CCCC Stock Price

View Fullscreen

CCCC RSI Chart

CCCC Valuation

Market Cap

443.1M

Price/Earnings (Trailing)

-3.51

Price/Sales (Trailing)

20.41

EV/EBITDA

-2.91

Price/Free Cashflow

-4.77

CCCC Price/Sales (Trailing)

CCCC Profitability

EBT Margin

-569.63%

Return on Equity

-48.81%

Return on Assets

-31.65%

Free Cashflow Yield

-20.98%

CCCC Fundamentals

CCCC Revenue

Revenue (TTM)

21.7M

Rev. Growth (Yr)

87.83%

Rev. Growth (Qtr)

-6.21%

CCCC Earnings

Earnings (TTM)

-126.1M

Earnings Growth (Yr)

18.46%

Earnings Growth (Qtr)

18.4%

Breaking Down CCCC Revenue

Last 7 days

2.7%

Last 30 days

36.3%

Last 90 days

4.1%

Trailing 12 Months

71.7%

How does CCCC drawdown profile look like?

CCCC Financial Health

Current Ratio

5.08

CCCC Investor Care

Shares Dilution (1Y)

40.24%

Diluted EPS (TTM)

-2.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	21.7M	0	0	0
2023	25.5M	14.3M	18.6M	19.9M
2022	46.0M	50.1M	48.3M	31.1M
2021	33.8M	33.9M	34.0M	45.8M
2020	24.3M	27.3M	30.2M	33.2M
2019	0	0	0	21.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About C4 Therapeutics Inc

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

CEO	Mr. Andrew J. Hirsch M.B.A.
WEBSITE	c4therapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	146

C4 Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for C4 Therapeutics Inc? What does CCCC stand for in stocks?

CCCC is the stock ticker symbol of C4 Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of C4 Therapeutics Inc (CCCC)?

As of Thu Jul 25 2024, market cap of C4 Therapeutics Inc is 443.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CCCC stock?

You can check CCCC's fair value in chart for subscribers.

Is C4 Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CCCC is over valued or under valued. Whether C4 Therapeutics Inc is cheap or expensive depends on the assumptions which impact C4 Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CCCC.

What is C4 Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, CCCC's PE ratio (Price to Earnings) is -3.51 and Price to Sales (PS) ratio is 20.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CCCC PE ratio will change depending on the future growth rate expectations of investors.